Sonoma Pharmaceuticals, Inc.SNOAEarnings & Financial Report
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on developing, manufacturing and selling dermatology and wound care products. It operates across North America, Europe and Asia, with offerings covering acne treatment, skin infection management, post-surgical wound recovery and chronic skin condition care for consumers and healthcare providers.
SNOA Q3 FY2026 Key Financial Metrics
Revenue
$4.3M
Gross Profit
$1.6M
Operating Profit
$-678.0K
Net Profit
$-819.0K
Gross Margin
37.9%
Operating Margin
-15.6%
Net Margin
-18.8%
YoY Growth
22.0%
EPS
$-0.48
Sonoma Pharmaceuticals, Inc. Q3 FY2026 Financial Summary
Sonoma Pharmaceuticals, Inc. reported revenue of $4.3M (up 22.0% YoY) for Q3 FY2026, with a net profit of $-819.0K (up 11.7% YoY) (-18.8% margin). Cost of goods sold was $2.7M, operating expenses totaled $2.3M.
Key Financial Metrics
| Total Revenue | $4.3M |
|---|---|
| Net Profit | $-819.0K |
| Gross Margin | 37.9% |
| Operating Margin | -15.6% |
| Report Period | Q3 FY2026 |
Revenue Breakdown
Sonoma Pharmaceuticals, Inc. Q3 FY2026 revenue of $4.3M breaks down across 2 segments, led by Products at $3.9M (88.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $3.9M | 88.8% |
| Other | $486.0K | 11.2% |
Sonoma Pharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Sonoma Pharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Other) has evolved quarter over quarter.
| Segment | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Products | $3.9M | $5.1M | $3.6M | $3.2M |
| Other | $486.0K | $488.0K | $460.0K | $560.0K |
Sonoma Pharmaceuticals, Inc. Annual Revenue by Year
Sonoma Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $14.3M).
Sonoma Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Sonoma Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $4.3M | +22.0% | $-819.0K | -18.8% |
| Q2 FY2026 | $5.6M | +56.6% | $-534.0K | -9.5% |
| Q1 FY2026 | $4.0M | +18.4% | $-1.2M | -30.9% |
| Q4 FY2025 | $3.8M | +9.2% | $-776.0K | -20.7% |
| Q3 FY2025 | $3.6M | +13.6% | $-928.0K | -26.0% |
| Q2 FY2025 | $3.6M | +31.1% | $-610.0K | -17.0% |
| Q1 FY2025 | $3.4M | -1.1% | $-1.1M | -33.7% |
| Q4 FY2024 | $3.4M | +14.1% | $-1.1M | -31.0% |
Income Statement
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $3.4M | $3.6M | $3.6M | $3.8M | $4.0M | $5.6M | $4.3M |
| YoY Growth | 14.1% | -1.1% | 31.1% | 13.6% | 9.2% | 18.4% | 56.6% | 22.0% |
Balance Sheet
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.7M | $13.7M | $13.7M | $13.7M | $13.7M | $14.6M | $13.9M | $13.6M |
| Liabilities | $8.6M | $8.7M | $8.3M | $8.8M | $9.3M | $10.5M | $10.1M | $10.2M |
| Equity | $6.1M | $5.0M | $5.4M | $4.9M | $4.4M | $4.1M | $3.8M | $3.4M |
Cash Flow
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $152000 | $-912000 | $354000 | $565000 | $-95000 | $-2.0M | $-635000 | $-764000 |